Project description
Profiling cancer response to drugs
Emerging evidence suggests that anti-cancer drugs targeting oncogene-associated products often lead to resistance, impeding therapy. Given that the mechanisms of drug resistance remain elusive, the EU-funded AML-SynergyX project aims to understand how acute myeloid leukaemia (AML) cells respond to small-molecule inhibitors against common AML gene rearrangements or targets such as FLT3 and MLL. Researchers will employ genetic and transcriptome technologies to profile the primary response and adaptation of cancer cells to drug inhibition. Overall, the work will assist in the design of new drugs and the choice of combinatorial treatments for improved clinical outcome.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF-EF-SE - Society and Enterprise panel
Coordinator
1030 Wien
Austria
See on map